Frequency of driver mutations across disease stages in Slovenian non-small cell lung cancer patients
This poster presents the first comprehensive analysis of actionable [...]
A large molecular model (LMM)-based predictor of clinical response to the WEE1 inhibitor Debio 0123 + carboplatin therapy
DNA Damage Response (DDR) dysregulation is a major factor [...]
The frequency of driver alterations in non-small cell lung cancer patients: Slovenian nationwide observational cohort trial
Next-generation sequencing (NGS) biomarker testing for all newly diagnosed [...]
Assessing confidence in genetic variants identified in RNA-seq data
RNA-seq data hold significant potential for identifying genetic variants. [...]
Prediction of sotorasib response duration and identification of clinically actionable resistance mechanisms using an RNA-based patient classifier
KRAS mutations are among the most prevalent oncogenic drivers [...]
Genialis™ Supermodel: Predicting monotherapy and combination therapy responses in KRAS-mutated cancers using a large molecular model of cancer biology
KRAS mutations drive approximately 25% of human cancers, resulting [...]
Biology-driven, machine learning-based development of a biomarker to predict response to WEE1 inhibitor Debio 0123
The WEE1 kinase is a central regulator of G2/M [...]
Molecular biomarker testing in Slovenian non-small cell lung cancer patients in early and late stages of the disease
Molecular biomarkers in non-small cell lung cancer (NSCLC), primarily [...]
Genialis™ krasID: Biology-driven Machine Learning to Personalize KRAS Inhibitor Therapy
KRAS inhibitors (KRASi) have the potential to transform treatment [...]
Genialis™ krasID: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapy
Genialis krasID analyzes foundational aspects of KRAS biology using RNA-sequencing [...]
